Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
Friday, The Lancet published a new pooled, participant-level analysis of patients with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction (HFpEF) from Novo Nordisk A/S' (NYSE:NVO) SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM trials.
週五，《柳葉刀》發佈了來自諾和諾德A/S（紐約證券交易所代碼：NVO）Select、FLOW、step-HFPEF和stepHFPEF Dm試驗中射血分數略有下降的心力衰竭患者或射血分數保持不變的心力衰竭患者的全新合併分析。
According to the analysis, semaglutide led to a 31% reduced risk of combined cardiovascular (CV) death or worsening heart failure (HF) events, based on an incidence of 5.4% in patients assigned to semaglutide versus 7.5% in those assigned to placebo.
根據分析，索瑪魯肽使合併心血管（CV）死亡或心力衰竭（HF）事件惡化的風險降低了31％，而分配給索馬魯肽的患者的發病率爲5.4％，而安慰劑患者的發病率爲7.5％。
Also Read: Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices.
另請閱讀：諾和諾德不以毒品卡特爾的身份運作，首席執行官爲美國對Ozempic的定價辯護，以免受到對藥品價格居高不下的批評。
Semaglutide is popularly available as Ozempic for diabetes and Wegovy for weight loss. Semaglutide also led to a 41% lower risk of worsening heart failure (2.8% versus 4.7% with placebo).
Semaglutide 通常以Ozempic的形式用於糖尿病，Wegovy的形式普遍用於減肥。索瑪魯肽還使心力衰竭惡化的風險降低了41％（2.8％，安慰劑爲4.7％）。
There was no significant effect on the incidence of CV death (3.1% with semaglutide versus 3.7% with placebo).
對心血管死亡發生率沒有顯著影響（索瑪魯肽爲 3.1%，安慰劑爲 3.7%）。
Statistical analyses were not adjusted for multiplicity, and hazard ratios should not be used to infer definitive treatment effects. The study was a pooled, post hoc participant-level analysis of 3,743 patients.
統計分析未根據多重性進行調整，也不應使用危害比率來推斷明確的治療效果。該研究是對3,743名患者進行的事後參與者級別的合併分析。
Adverse events leading to treatment discontinuation occurred in 21% of patients in the semaglutide group and 13.9% in the placebo group.
導致停止治療的不良事件發生在索瑪魯肽組的患者中有21％，在安慰劑組中發生13.9％的患者。
Gastrointestinal disorders leading to treatment discontinuation occurred in 11.1% of patients in the semaglutide group and 2.7% in the placebo group.
導致停止治療的胃腸道疾病發生在索瑪魯肽組的患者中有11.1％，在安慰劑組中出現2.7％的患者。
Semaglutide is not approved in the US to reduce heart failure outcomes.
Semaglutide在美國未獲批准用於減少心力衰竭的結果。
Research also showed that GLP-1 agonists, drugs like Ozempic, Wegovy, and Eli Lilly And Co's (NYSE:LLY) Zepbound, are investigating their potential to address a range of other conditions, including addiction, sleep apnea, and even cancer.
研究還表明，GLP-1 激動劑，即Ozempic、Wegovy和禮來公司（紐約證券交易所代碼：LLY）Zepbound等藥物，正在研究其治療一系列其他疾病的潛力，包括成癮、睡眠呼吸暫停甚至癌症。
These medications are showing early promise in preventing several common cancers linked to obesity, such as breast, colon, liver, and ovarian cancers, by acting on the brain to regulate hormones, slow digestion, and reduce hunger.
這些藥物通過作用於大腦調節激素、減緩消化和減少飢餓感，在預防幾種與肥胖相關的常見癌症（例如乳腺癌、結腸癌、肝癌和卵巢癌）方面顯示出早期的希望。
Price Action: At last check on Friday, NVO stock was up 0.80% at $138.61.
價格走勢：在週五的最後一次檢查中，NVO股價上漲0.80％，至138.61美元。
- NuCana Stock Plunges On Colorectal Combo Therapy Trial Setback, Ends Mid-Stage Study After Disappointing Data.
- NuCana股票因結直腸組合療法試驗受挫而暴跌，在令人失望的數據後結束了中期研究。
Image Via Shutterstock
圖片來自 Shutterstock